secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2026-06-12T20:06:58+00:00
Accession:  0001534120-26-000040
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.02, 3.03, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo exchanges Series C shares to lift beneficial ownership cap; revises exec severance
--------------------------------------------------------------------------------

- Exchanged 4,294.675 Series C shares for new Series C-1 shares, removing restriction that capped beneficial ownership at 4.99% (now 9.99%).
- After exchange, 4,085.379 Series C shares remain outstanding.
- Amended employment agreements for CEO Neil, CFO Sullivan, CMO Doyle, and CBO Boyd, changing severance and change-in-control terms.
- CEO Neil gets 18-month base salary severance (others 12 months); on change-in-control termination, 1.5x base + 1x target bonus (others 1x/1x).
- Pre-amendment options vest fully on qualifying termination; exercise period extended to 12 months for CEO/CFO, 6 months for CMO/CBO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000153412026000040/0001534120-26-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000153412026000040/avtx-20260611.htm
  HTML page:      https://secwatch.observer/filing/0001534120-26-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer